Hemostasis biomarkers in multiple sclerosis

The aim was to investigate the plasma levels of hemostasis components in multiple sclerosis (MS) and their association with clinical and magnetic resonance imaging (MRI) outcomes.

[1]  S. Kanse,et al.  Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages. , 2017, Biochemical and biophysical research communications.

[2]  R. Perera,et al.  Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex , 2017, Annals of neurology.

[3]  T. Dimitroulas,et al.  Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis , 2017, Front. Med..

[4]  B. Isermann,et al.  Thrombomodulin‐dependent protein C activation is required for mitochondrial function and myelination in the central nervous system , 2016, Journal of thrombosis and haemostasis : JTH.

[5]  A. Kocer,et al.  The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis. , 2016, Multiple sclerosis and related disorders.

[6]  R. Takahashi,et al.  Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report , 2016, CEN Case Reports.

[7]  E. Haacke,et al.  Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. , 2016, Radiology.

[8]  C. Ruppert,et al.  Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells , 2016, Nature Communications.

[9]  R. Pawlinski,et al.  Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation. , 2016, Thrombosis research.

[10]  Sara G. Murray,et al.  Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation , 2015, Nature Communications.

[11]  Ping Cai,et al.  Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage , 2015, Stroke.

[12]  G. Lippi,et al.  Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review , 2014, Seminars in Thrombosis & Hemostasis.

[13]  B. Peterlin,et al.  The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis , 2014, Disease markers.

[14]  E. Rostrup,et al.  Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI☆☆☆ , 2013, NeuroImage: Clinical.

[15]  X. Zheng.  Structure–function and regulation of ADAMTS‐13 protease , 2013, Journal of thrombosis and haemostasis : JTH.

[16]  S. Lynch,et al.  Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication , 2012, Journal of the Neurological Sciences.

[17]  S. Kato,et al.  Heparin Cofactor II, a Serine Protease Inhibitor, Promotes Angiogenesis via Activation of the AMP-activated Protein Kinase-Endothelial Nitric-oxide Synthase Signaling Pathway , 2012, The Journal of Biological Chemistry.

[18]  A. Chu.  Tissue Factor, Blood Coagulation, and Beyond: An Overview , 2011, International journal of inflammation.

[19]  R. Benedict,et al.  Risk factors for and management of cognitive dysfunction in multiple sclerosis , 2011, Nature Reviews Neurology.

[20]  Sergio E. Baranzini,et al.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.

[21]  C. Esmon,et al.  Inflammation and the activated protein C anticoagulant pathway. , 2006, Seminars in thrombosis and hemostasis.

[22]  M. Cuzner,et al.  Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. , 2003, Brain : a journal of neurology.

[23]  Y. Itoyama,et al.  Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. , 1999, The Tohoku journal of experimental medicine.

[24]  S. Coughlin,et al.  How the protease thrombin talks to cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Salmaggi,et al.  Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients , 1998, Journal of Neuroimmunology.

[26]  A. Vaheri,et al.  Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. , 1997, Journal of clinical pathology.

[27]  N. Yanagisawa,et al.  Thrombomodulin in the sera of patients with multiple sclerosis and human lymphotropic virus type-1-associated myelopathy , 1995, Journal of Neuroimmunology.

[28]  K. Hajjar,et al.  Fibrinolysis and the control of blood coagulation. , 2015, Blood reviews.

[29]  J. Subra,et al.  Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis , 2013, International Urology and Nephrology.